The relationship between plasma lipid peroxidation products and primary graft dysfunction after lung transplantation is modified by donor smoking and reperfusion hyperoxia
Background Donor smoking history and higher fraction of inspired oxygen (F io2 ) at reperfusion are associated with primary graft dysfunction (PGD) after lung transplantation. We hypothesized that oxidative injury biomarkers would be elevated in PGD, with higher levels associated with donor exposure...
Gespeichert in:
| Veröffentlicht in: | The Journal of heart and lung transplantation 2016-04, Vol.35 (4), p.500-507 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 507 |
|---|---|
| container_issue | 4 |
| container_start_page | 500 |
| container_title | The Journal of heart and lung transplantation |
| container_volume | 35 |
| creator | Diamond, Joshua M., MD, MS Porteous, Mary K., MD, MS Jackson Roberts, L., MD Wickersham, Nancy, BS Rushefski, Melanie Kawut, Steven M., MD, MS Shah, Rupal J., MD, MS Cantu, Edward, MD, MS Lederer, David J., MD, MS Chatterjee, Shampa, PhD Lama, Vibha N., MD, MS Bhorade, Sangeeta, MD Crespo, Maria, MD McDyer, John, MD Wille, Keith, MD Orens, Jonathan, MD Weinacker, Ann, MD Arcasoy, Selim, MD Shah, Pali D., MD Wilkes, David S., MD Hage, Chadi, MD Palmer, Scott M., MD, MHS Snyder, Laurie, MD Calfee, Carolyn S., MD Ware, Lorraine B., MD Christie, Jason D., MD, MS |
| description | Background Donor smoking history and higher fraction of inspired oxygen (F io2 ) at reperfusion are associated with primary graft dysfunction (PGD) after lung transplantation. We hypothesized that oxidative injury biomarkers would be elevated in PGD, with higher levels associated with donor exposure to cigarette smoke and recipient hyperoxia at reperfusion. Methods We performed a nested case-control study of 72 lung transplant recipients from the Lung Transplant Outcomes Group cohort. Using mass spectroscopy, F2 -isoprostanes and isofurans were measured in plasma collected after transplantation. Cases were defined in 2 ways: grade 3 PGD present at day 2 or day 3 after reperfusion (severe PGD) or any grade 3 PGD (any PGD). Results There were 31 severe PGD cases with 41 controls and 35 any PGD cases with 37 controls. Plasma F2 -isoprostane levels were higher in severe PGD cases compared with controls (28.6 pg/ml vs 19.8 pg/ml, p = 0.03). Plasma F2 -isoprostane levels were higher in severe PGD cases compared with controls (29.6 pg/ml vs 19.0 pg/ml, p = 0.03) among patients reperfused with F io2 >40%. Among recipients of lungs from donors with smoke exposure, plasma F2 -isoprostane (38.2 pg/ml vs 22.5 pg/ml, p = 0.046) and isofuran (66.9 pg/ml vs 34.6 pg/ml, p = 0.046) levels were higher in severe PGD compared with control subjects. Conclusions Plasma levels of lipid peroxidation products are higher in patients with severe PGD, in recipients of lungs from donors with smoke exposure, and in recipients exposed to higher F io2 at reperfusion. Oxidative injury is an important mechanism of PGD and may be magnified by donor exposure to cigarette smoke and hyperoxia at reperfusion. |
| doi_str_mv | 10.1016/j.healun.2015.12.012 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4821817</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1053249816000073</els_id><sourcerecordid>1779024340</sourcerecordid><originalsourceid>FETCH-LOGICAL-c518t-78a00eec9cdd82530e8c29f458a11ebbed4fcf85cf94f5428138ffd0ded0f65d3</originalsourceid><addsrcrecordid>eNqFUstu1TAQjRCIlsIfIOQlmwTbiRNng4QqXlIlFpS15djjG98mdrCTQr6Jn8RpLuWxYeWx5sw5M3Mmy54TXBBM6lfHogc5LK6gmLCC0AIT-iA7J4w1eUlI8zDFmJU5rVp-lj2J8YgxpiWjj7MzWnNW13Vznv247gEFGORsvYu9nVAH8zcAh6ZBxlGiwU5WowmC_271HQpNwetFzRFJlzLBjjKs6BCkmZFeo1mcuoOlPwSUOjygOUgXE6GbdwYb0ei1NRY06lakvfMBxdHf2ATeWAMkRbPEDdyvu7p8mj0ycojw7PReZF_evb2-_JBffXr_8fLNVa4Y4XPecIkxgGqV1pyyEgNXtDUV45IQ6DrQlVGGM2XayrCKclJyYzTWoLGpmS4vstc777R0I2gFLvU_iNOkwksr_s4424uDvxUVp4STJhG8PBEE_3WBOIvRRgVDWgD4JQrSNC2mVVnhBK12qAo-xgDmXoZgsfksjmL3WWw-C0JF8jmVvfizxfuiX8b-ngHSom4tBBGVBadA2wBqFtrb_yn8S6AG66ySww2sEI9-CS6ZIIiIqUB83m5tOzVSpzPDTVn-BEFm2IM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1779024340</pqid></control><display><type>article</type><title>The relationship between plasma lipid peroxidation products and primary graft dysfunction after lung transplantation is modified by donor smoking and reperfusion hyperoxia</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Diamond, Joshua M., MD, MS ; Porteous, Mary K., MD, MS ; Jackson Roberts, L., MD ; Wickersham, Nancy, BS ; Rushefski, Melanie ; Kawut, Steven M., MD, MS ; Shah, Rupal J., MD, MS ; Cantu, Edward, MD, MS ; Lederer, David J., MD, MS ; Chatterjee, Shampa, PhD ; Lama, Vibha N., MD, MS ; Bhorade, Sangeeta, MD ; Crespo, Maria, MD ; McDyer, John, MD ; Wille, Keith, MD ; Orens, Jonathan, MD ; Weinacker, Ann, MD ; Arcasoy, Selim, MD ; Shah, Pali D., MD ; Wilkes, David S., MD ; Hage, Chadi, MD ; Palmer, Scott M., MD, MHS ; Snyder, Laurie, MD ; Calfee, Carolyn S., MD ; Ware, Lorraine B., MD ; Christie, Jason D., MD, MS</creator><creatorcontrib>Diamond, Joshua M., MD, MS ; Porteous, Mary K., MD, MS ; Jackson Roberts, L., MD ; Wickersham, Nancy, BS ; Rushefski, Melanie ; Kawut, Steven M., MD, MS ; Shah, Rupal J., MD, MS ; Cantu, Edward, MD, MS ; Lederer, David J., MD, MS ; Chatterjee, Shampa, PhD ; Lama, Vibha N., MD, MS ; Bhorade, Sangeeta, MD ; Crespo, Maria, MD ; McDyer, John, MD ; Wille, Keith, MD ; Orens, Jonathan, MD ; Weinacker, Ann, MD ; Arcasoy, Selim, MD ; Shah, Pali D., MD ; Wilkes, David S., MD ; Hage, Chadi, MD ; Palmer, Scott M., MD, MHS ; Snyder, Laurie, MD ; Calfee, Carolyn S., MD ; Ware, Lorraine B., MD ; Christie, Jason D., MD, MS ; for the Lung Transplant Outcomes Group ; Lung Transplant Outcomes Group</creatorcontrib><description>Background Donor smoking history and higher fraction of inspired oxygen (F io2 ) at reperfusion are associated with primary graft dysfunction (PGD) after lung transplantation. We hypothesized that oxidative injury biomarkers would be elevated in PGD, with higher levels associated with donor exposure to cigarette smoke and recipient hyperoxia at reperfusion. Methods We performed a nested case-control study of 72 lung transplant recipients from the Lung Transplant Outcomes Group cohort. Using mass spectroscopy, F2 -isoprostanes and isofurans were measured in plasma collected after transplantation. Cases were defined in 2 ways: grade 3 PGD present at day 2 or day 3 after reperfusion (severe PGD) or any grade 3 PGD (any PGD). Results There were 31 severe PGD cases with 41 controls and 35 any PGD cases with 37 controls. Plasma F2 -isoprostane levels were higher in severe PGD cases compared with controls (28.6 pg/ml vs 19.8 pg/ml, p = 0.03). Plasma F2 -isoprostane levels were higher in severe PGD cases compared with controls (29.6 pg/ml vs 19.0 pg/ml, p = 0.03) among patients reperfused with F io2 >40%. Among recipients of lungs from donors with smoke exposure, plasma F2 -isoprostane (38.2 pg/ml vs 22.5 pg/ml, p = 0.046) and isofuran (66.9 pg/ml vs 34.6 pg/ml, p = 0.046) levels were higher in severe PGD compared with control subjects. Conclusions Plasma levels of lipid peroxidation products are higher in patients with severe PGD, in recipients of lungs from donors with smoke exposure, and in recipients exposed to higher F io2 at reperfusion. Oxidative injury is an important mechanism of PGD and may be magnified by donor exposure to cigarette smoke and hyperoxia at reperfusion.</description><identifier>ISSN: 1053-2498</identifier><identifier>EISSN: 1557-3117</identifier><identifier>DOI: 10.1016/j.healun.2015.12.012</identifier><identifier>PMID: 26856667</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Biomarkers - blood ; F2-isoprostane ; Female ; Follow-Up Studies ; Humans ; Hyperoxia - blood ; Hyperoxia - etiology ; ischemia reperfusion ; isofuran ; Lipid Peroxidation ; lung transplantation ; Lung Transplantation - adverse effects ; Male ; Postoperative Complications ; primary graft dysfunction ; Primary Graft Dysfunction - blood ; Primary Graft Dysfunction - etiology ; Reperfusion Injury - blood ; Reperfusion Injury - complications ; Retrospective Studies ; Smoking - adverse effects ; Surgery ; Time Factors ; Tissue Donors</subject><ispartof>The Journal of heart and lung transplantation, 2016-04, Vol.35 (4), p.500-507</ispartof><rights>International Society for Heart and Lung Transplantation</rights><rights>2016 International Society for Heart and Lung Transplantation</rights><rights>Copyright © 2016 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c518t-78a00eec9cdd82530e8c29f458a11ebbed4fcf85cf94f5428138ffd0ded0f65d3</citedby><cites>FETCH-LOGICAL-c518t-78a00eec9cdd82530e8c29f458a11ebbed4fcf85cf94f5428138ffd0ded0f65d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1053249816000073$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26856667$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Diamond, Joshua M., MD, MS</creatorcontrib><creatorcontrib>Porteous, Mary K., MD, MS</creatorcontrib><creatorcontrib>Jackson Roberts, L., MD</creatorcontrib><creatorcontrib>Wickersham, Nancy, BS</creatorcontrib><creatorcontrib>Rushefski, Melanie</creatorcontrib><creatorcontrib>Kawut, Steven M., MD, MS</creatorcontrib><creatorcontrib>Shah, Rupal J., MD, MS</creatorcontrib><creatorcontrib>Cantu, Edward, MD, MS</creatorcontrib><creatorcontrib>Lederer, David J., MD, MS</creatorcontrib><creatorcontrib>Chatterjee, Shampa, PhD</creatorcontrib><creatorcontrib>Lama, Vibha N., MD, MS</creatorcontrib><creatorcontrib>Bhorade, Sangeeta, MD</creatorcontrib><creatorcontrib>Crespo, Maria, MD</creatorcontrib><creatorcontrib>McDyer, John, MD</creatorcontrib><creatorcontrib>Wille, Keith, MD</creatorcontrib><creatorcontrib>Orens, Jonathan, MD</creatorcontrib><creatorcontrib>Weinacker, Ann, MD</creatorcontrib><creatorcontrib>Arcasoy, Selim, MD</creatorcontrib><creatorcontrib>Shah, Pali D., MD</creatorcontrib><creatorcontrib>Wilkes, David S., MD</creatorcontrib><creatorcontrib>Hage, Chadi, MD</creatorcontrib><creatorcontrib>Palmer, Scott M., MD, MHS</creatorcontrib><creatorcontrib>Snyder, Laurie, MD</creatorcontrib><creatorcontrib>Calfee, Carolyn S., MD</creatorcontrib><creatorcontrib>Ware, Lorraine B., MD</creatorcontrib><creatorcontrib>Christie, Jason D., MD, MS</creatorcontrib><creatorcontrib>for the Lung Transplant Outcomes Group</creatorcontrib><creatorcontrib>Lung Transplant Outcomes Group</creatorcontrib><title>The relationship between plasma lipid peroxidation products and primary graft dysfunction after lung transplantation is modified by donor smoking and reperfusion hyperoxia</title><title>The Journal of heart and lung transplantation</title><addtitle>J Heart Lung Transplant</addtitle><description>Background Donor smoking history and higher fraction of inspired oxygen (F io2 ) at reperfusion are associated with primary graft dysfunction (PGD) after lung transplantation. We hypothesized that oxidative injury biomarkers would be elevated in PGD, with higher levels associated with donor exposure to cigarette smoke and recipient hyperoxia at reperfusion. Methods We performed a nested case-control study of 72 lung transplant recipients from the Lung Transplant Outcomes Group cohort. Using mass spectroscopy, F2 -isoprostanes and isofurans were measured in plasma collected after transplantation. Cases were defined in 2 ways: grade 3 PGD present at day 2 or day 3 after reperfusion (severe PGD) or any grade 3 PGD (any PGD). Results There were 31 severe PGD cases with 41 controls and 35 any PGD cases with 37 controls. Plasma F2 -isoprostane levels were higher in severe PGD cases compared with controls (28.6 pg/ml vs 19.8 pg/ml, p = 0.03). Plasma F2 -isoprostane levels were higher in severe PGD cases compared with controls (29.6 pg/ml vs 19.0 pg/ml, p = 0.03) among patients reperfused with F io2 >40%. Among recipients of lungs from donors with smoke exposure, plasma F2 -isoprostane (38.2 pg/ml vs 22.5 pg/ml, p = 0.046) and isofuran (66.9 pg/ml vs 34.6 pg/ml, p = 0.046) levels were higher in severe PGD compared with control subjects. Conclusions Plasma levels of lipid peroxidation products are higher in patients with severe PGD, in recipients of lungs from donors with smoke exposure, and in recipients exposed to higher F io2 at reperfusion. Oxidative injury is an important mechanism of PGD and may be magnified by donor exposure to cigarette smoke and hyperoxia at reperfusion.</description><subject>Adult</subject><subject>Biomarkers - blood</subject><subject>F2-isoprostane</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Hyperoxia - blood</subject><subject>Hyperoxia - etiology</subject><subject>ischemia reperfusion</subject><subject>isofuran</subject><subject>Lipid Peroxidation</subject><subject>lung transplantation</subject><subject>Lung Transplantation - adverse effects</subject><subject>Male</subject><subject>Postoperative Complications</subject><subject>primary graft dysfunction</subject><subject>Primary Graft Dysfunction - blood</subject><subject>Primary Graft Dysfunction - etiology</subject><subject>Reperfusion Injury - blood</subject><subject>Reperfusion Injury - complications</subject><subject>Retrospective Studies</subject><subject>Smoking - adverse effects</subject><subject>Surgery</subject><subject>Time Factors</subject><subject>Tissue Donors</subject><issn>1053-2498</issn><issn>1557-3117</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUstu1TAQjRCIlsIfIOQlmwTbiRNng4QqXlIlFpS15djjG98mdrCTQr6Jn8RpLuWxYeWx5sw5M3Mmy54TXBBM6lfHogc5LK6gmLCC0AIT-iA7J4w1eUlI8zDFmJU5rVp-lj2J8YgxpiWjj7MzWnNW13Vznv247gEFGORsvYu9nVAH8zcAh6ZBxlGiwU5WowmC_271HQpNwetFzRFJlzLBjjKs6BCkmZFeo1mcuoOlPwSUOjygOUgXE6GbdwYb0ei1NRY06lakvfMBxdHf2ATeWAMkRbPEDdyvu7p8mj0ycojw7PReZF_evb2-_JBffXr_8fLNVa4Y4XPecIkxgGqV1pyyEgNXtDUV45IQ6DrQlVGGM2XayrCKclJyYzTWoLGpmS4vstc777R0I2gFLvU_iNOkwksr_s4424uDvxUVp4STJhG8PBEE_3WBOIvRRgVDWgD4JQrSNC2mVVnhBK12qAo-xgDmXoZgsfksjmL3WWw-C0JF8jmVvfizxfuiX8b-ngHSom4tBBGVBadA2wBqFtrb_yn8S6AG66ySww2sEI9-CS6ZIIiIqUB83m5tOzVSpzPDTVn-BEFm2IM</recordid><startdate>20160401</startdate><enddate>20160401</enddate><creator>Diamond, Joshua M., MD, MS</creator><creator>Porteous, Mary K., MD, MS</creator><creator>Jackson Roberts, L., MD</creator><creator>Wickersham, Nancy, BS</creator><creator>Rushefski, Melanie</creator><creator>Kawut, Steven M., MD, MS</creator><creator>Shah, Rupal J., MD, MS</creator><creator>Cantu, Edward, MD, MS</creator><creator>Lederer, David J., MD, MS</creator><creator>Chatterjee, Shampa, PhD</creator><creator>Lama, Vibha N., MD, MS</creator><creator>Bhorade, Sangeeta, MD</creator><creator>Crespo, Maria, MD</creator><creator>McDyer, John, MD</creator><creator>Wille, Keith, MD</creator><creator>Orens, Jonathan, MD</creator><creator>Weinacker, Ann, MD</creator><creator>Arcasoy, Selim, MD</creator><creator>Shah, Pali D., MD</creator><creator>Wilkes, David S., MD</creator><creator>Hage, Chadi, MD</creator><creator>Palmer, Scott M., MD, MHS</creator><creator>Snyder, Laurie, MD</creator><creator>Calfee, Carolyn S., MD</creator><creator>Ware, Lorraine B., MD</creator><creator>Christie, Jason D., MD, MS</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160401</creationdate><title>The relationship between plasma lipid peroxidation products and primary graft dysfunction after lung transplantation is modified by donor smoking and reperfusion hyperoxia</title><author>Diamond, Joshua M., MD, MS ; Porteous, Mary K., MD, MS ; Jackson Roberts, L., MD ; Wickersham, Nancy, BS ; Rushefski, Melanie ; Kawut, Steven M., MD, MS ; Shah, Rupal J., MD, MS ; Cantu, Edward, MD, MS ; Lederer, David J., MD, MS ; Chatterjee, Shampa, PhD ; Lama, Vibha N., MD, MS ; Bhorade, Sangeeta, MD ; Crespo, Maria, MD ; McDyer, John, MD ; Wille, Keith, MD ; Orens, Jonathan, MD ; Weinacker, Ann, MD ; Arcasoy, Selim, MD ; Shah, Pali D., MD ; Wilkes, David S., MD ; Hage, Chadi, MD ; Palmer, Scott M., MD, MHS ; Snyder, Laurie, MD ; Calfee, Carolyn S., MD ; Ware, Lorraine B., MD ; Christie, Jason D., MD, MS</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c518t-78a00eec9cdd82530e8c29f458a11ebbed4fcf85cf94f5428138ffd0ded0f65d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Biomarkers - blood</topic><topic>F2-isoprostane</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Hyperoxia - blood</topic><topic>Hyperoxia - etiology</topic><topic>ischemia reperfusion</topic><topic>isofuran</topic><topic>Lipid Peroxidation</topic><topic>lung transplantation</topic><topic>Lung Transplantation - adverse effects</topic><topic>Male</topic><topic>Postoperative Complications</topic><topic>primary graft dysfunction</topic><topic>Primary Graft Dysfunction - blood</topic><topic>Primary Graft Dysfunction - etiology</topic><topic>Reperfusion Injury - blood</topic><topic>Reperfusion Injury - complications</topic><topic>Retrospective Studies</topic><topic>Smoking - adverse effects</topic><topic>Surgery</topic><topic>Time Factors</topic><topic>Tissue Donors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Diamond, Joshua M., MD, MS</creatorcontrib><creatorcontrib>Porteous, Mary K., MD, MS</creatorcontrib><creatorcontrib>Jackson Roberts, L., MD</creatorcontrib><creatorcontrib>Wickersham, Nancy, BS</creatorcontrib><creatorcontrib>Rushefski, Melanie</creatorcontrib><creatorcontrib>Kawut, Steven M., MD, MS</creatorcontrib><creatorcontrib>Shah, Rupal J., MD, MS</creatorcontrib><creatorcontrib>Cantu, Edward, MD, MS</creatorcontrib><creatorcontrib>Lederer, David J., MD, MS</creatorcontrib><creatorcontrib>Chatterjee, Shampa, PhD</creatorcontrib><creatorcontrib>Lama, Vibha N., MD, MS</creatorcontrib><creatorcontrib>Bhorade, Sangeeta, MD</creatorcontrib><creatorcontrib>Crespo, Maria, MD</creatorcontrib><creatorcontrib>McDyer, John, MD</creatorcontrib><creatorcontrib>Wille, Keith, MD</creatorcontrib><creatorcontrib>Orens, Jonathan, MD</creatorcontrib><creatorcontrib>Weinacker, Ann, MD</creatorcontrib><creatorcontrib>Arcasoy, Selim, MD</creatorcontrib><creatorcontrib>Shah, Pali D., MD</creatorcontrib><creatorcontrib>Wilkes, David S., MD</creatorcontrib><creatorcontrib>Hage, Chadi, MD</creatorcontrib><creatorcontrib>Palmer, Scott M., MD, MHS</creatorcontrib><creatorcontrib>Snyder, Laurie, MD</creatorcontrib><creatorcontrib>Calfee, Carolyn S., MD</creatorcontrib><creatorcontrib>Ware, Lorraine B., MD</creatorcontrib><creatorcontrib>Christie, Jason D., MD, MS</creatorcontrib><creatorcontrib>for the Lung Transplant Outcomes Group</creatorcontrib><creatorcontrib>Lung Transplant Outcomes Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of heart and lung transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Diamond, Joshua M., MD, MS</au><au>Porteous, Mary K., MD, MS</au><au>Jackson Roberts, L., MD</au><au>Wickersham, Nancy, BS</au><au>Rushefski, Melanie</au><au>Kawut, Steven M., MD, MS</au><au>Shah, Rupal J., MD, MS</au><au>Cantu, Edward, MD, MS</au><au>Lederer, David J., MD, MS</au><au>Chatterjee, Shampa, PhD</au><au>Lama, Vibha N., MD, MS</au><au>Bhorade, Sangeeta, MD</au><au>Crespo, Maria, MD</au><au>McDyer, John, MD</au><au>Wille, Keith, MD</au><au>Orens, Jonathan, MD</au><au>Weinacker, Ann, MD</au><au>Arcasoy, Selim, MD</au><au>Shah, Pali D., MD</au><au>Wilkes, David S., MD</au><au>Hage, Chadi, MD</au><au>Palmer, Scott M., MD, MHS</au><au>Snyder, Laurie, MD</au><au>Calfee, Carolyn S., MD</au><au>Ware, Lorraine B., MD</au><au>Christie, Jason D., MD, MS</au><aucorp>for the Lung Transplant Outcomes Group</aucorp><aucorp>Lung Transplant Outcomes Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The relationship between plasma lipid peroxidation products and primary graft dysfunction after lung transplantation is modified by donor smoking and reperfusion hyperoxia</atitle><jtitle>The Journal of heart and lung transplantation</jtitle><addtitle>J Heart Lung Transplant</addtitle><date>2016-04-01</date><risdate>2016</risdate><volume>35</volume><issue>4</issue><spage>500</spage><epage>507</epage><pages>500-507</pages><issn>1053-2498</issn><eissn>1557-3117</eissn><abstract>Background Donor smoking history and higher fraction of inspired oxygen (F io2 ) at reperfusion are associated with primary graft dysfunction (PGD) after lung transplantation. We hypothesized that oxidative injury biomarkers would be elevated in PGD, with higher levels associated with donor exposure to cigarette smoke and recipient hyperoxia at reperfusion. Methods We performed a nested case-control study of 72 lung transplant recipients from the Lung Transplant Outcomes Group cohort. Using mass spectroscopy, F2 -isoprostanes and isofurans were measured in plasma collected after transplantation. Cases were defined in 2 ways: grade 3 PGD present at day 2 or day 3 after reperfusion (severe PGD) or any grade 3 PGD (any PGD). Results There were 31 severe PGD cases with 41 controls and 35 any PGD cases with 37 controls. Plasma F2 -isoprostane levels were higher in severe PGD cases compared with controls (28.6 pg/ml vs 19.8 pg/ml, p = 0.03). Plasma F2 -isoprostane levels were higher in severe PGD cases compared with controls (29.6 pg/ml vs 19.0 pg/ml, p = 0.03) among patients reperfused with F io2 >40%. Among recipients of lungs from donors with smoke exposure, plasma F2 -isoprostane (38.2 pg/ml vs 22.5 pg/ml, p = 0.046) and isofuran (66.9 pg/ml vs 34.6 pg/ml, p = 0.046) levels were higher in severe PGD compared with control subjects. Conclusions Plasma levels of lipid peroxidation products are higher in patients with severe PGD, in recipients of lungs from donors with smoke exposure, and in recipients exposed to higher F io2 at reperfusion. Oxidative injury is an important mechanism of PGD and may be magnified by donor exposure to cigarette smoke and hyperoxia at reperfusion.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>26856667</pmid><doi>10.1016/j.healun.2015.12.012</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1053-2498 |
| ispartof | The Journal of heart and lung transplantation, 2016-04, Vol.35 (4), p.500-507 |
| issn | 1053-2498 1557-3117 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4821817 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Biomarkers - blood F2-isoprostane Female Follow-Up Studies Humans Hyperoxia - blood Hyperoxia - etiology ischemia reperfusion isofuran Lipid Peroxidation lung transplantation Lung Transplantation - adverse effects Male Postoperative Complications primary graft dysfunction Primary Graft Dysfunction - blood Primary Graft Dysfunction - etiology Reperfusion Injury - blood Reperfusion Injury - complications Retrospective Studies Smoking - adverse effects Surgery Time Factors Tissue Donors |
| title | The relationship between plasma lipid peroxidation products and primary graft dysfunction after lung transplantation is modified by donor smoking and reperfusion hyperoxia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T16%3A38%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20relationship%20between%20plasma%20lipid%20peroxidation%20products%20and%20primary%20graft%20dysfunction%20after%20lung%20transplantation%20is%20modified%20by%20donor%20smoking%20and%20reperfusion%20hyperoxia&rft.jtitle=The%20Journal%20of%20heart%20and%20lung%20transplantation&rft.au=Diamond,%20Joshua%20M.,%20MD,%20MS&rft.aucorp=for%20the%20Lung%20Transplant%20Outcomes%20Group&rft.date=2016-04-01&rft.volume=35&rft.issue=4&rft.spage=500&rft.epage=507&rft.pages=500-507&rft.issn=1053-2498&rft.eissn=1557-3117&rft_id=info:doi/10.1016/j.healun.2015.12.012&rft_dat=%3Cproquest_pubme%3E1779024340%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1779024340&rft_id=info:pmid/26856667&rft_els_id=S1053249816000073&rfr_iscdi=true |